Polaryx Therapeutics, Inc. Common Stock
NASDAQ Global MarketTotal Valuation
Polaryx Therapeutics, Inc. Common Stock carries a market capitalization of 96.70M, placing it among publicly traded companies globally.
| Market Cap | 96.70M |
| Enterprise Value | N/A |
Share Statistics
Polaryx Therapeutics, Inc. Common Stock currently has 49.85M shares outstanding.
| Shares Outstanding | 49.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 12.12 |
| P/TBV Ratio | 12.12 |
| P/FCF Ratio | -21.80 |
| P/OCF Ratio | -21.80 |
Financial Position
Polaryx Therapeutics, Inc. Common Stock maintains a current ratio of 13.53, meaning it holds 13.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.53 |
| Quick Ratio | 13.22 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -96.56 |
| Return on Assets (ROA) | -89.21 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Polaryx Therapeutics, Inc. Common Stock's stock has declined approximately -94.45714% over the past 52 weeks. The 50-day moving average sits at 2.07, while the 200-day moving average is 3.74.
| Beta (5Y) | N/A |
| 52-Week Price Change | -94.45714% |
| 50-Day Moving Average | 2.07 |
| 200-Day Moving Average | 3.74 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -5.22M, while operating income came in at -5.22M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -5.22M |
| Pretax Income | -6.85M |
| Net Income | -6.85M |
| EBITDA | -5.22M |
| EBIT | -5.22M |
| Earnings Per Share (EPS) | -0.14 |
Balance Sheet
Total book value stands at 10.94M, with working capital of 10.94M providing operational flexibility.
| Cash & Cash Equivalents | 11.54M |
| Total Debt | N/A |
| Net Debt | -11.54M |
| Equity (Book Value) | 10.94M |
| Book Value Per Share | 0.22 |
| Working Capital | 10.94M |
Cash Flow
Polaryx Therapeutics, Inc. Common Stock produced -5.81M in operating cash flow over the past twelve months.
| Operating Cash Flow | -5.81M |
| Capital Expenditures | N/A |
| Free Cash Flow | -5.81M |
| FCF Per Share | -0.12 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.59 |
| FCF Yield | -4.59 |
Scores
Polaryx Therapeutics, Inc. Common Stock posts an Altman Z-Score of 78.51, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 78.51 |